These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37409613)

  • 1. Predictive and prognostic role of early apolipoprotein A-I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti-PD-1 therapy.
    Xiao BJ; Sima XX; Chen G; Gulizeba H; Zhou T; Huang Y
    Cancer Med; 2023 Aug; 12(16):16918-16928. PubMed ID: 37409613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
    Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis.
    Xiao B; Ouyang H; Gulizeba H; Fu H; Wang Z; Huang Y
    Cancer Immunol Immunother; 2023 Nov; 72(11):3683-3692. PubMed ID: 37589756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma.
    Jiang R; Yang ZH; Luo DH; Guo L; Sun R; Chen QY; Huang PY; Qiu F; Zou X; Cao KJ; Mai HQ; Guo X; Qian CN; Hong MH; Chen MY
    Med Oncol; 2014 Aug; 31(8):80. PubMed ID: 25023050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
    Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
    Luo XL; Zhong GZ; Hu LY; Chen J; Liang Y; Chen QY; Liu Q; Rao HL; Chen KL; Cai QQ
    Oncotarget; 2015 Dec; 6(41):44037-48. PubMed ID: 26503474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
    Adkins DR; Haddad RI
    Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
    Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
    Front Immunol; 2021; 12():762663. PubMed ID: 34777379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.
    Mesia R; Bossi P; Hansen AR; Hsieh CY; Licitra LF; Tan EH; Chen P; Miller J; Siu LL; Haddad RI
    Eur J Cancer; 2019 Dec; 123():138-145. PubMed ID: 31698327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
    Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
    Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
    Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
    Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
    You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
    Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.
    Ali WAS; Huang X; Wu Y; Ma Y; Pan H; Liao J; Yang Z; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
    Cancer Control; 2023; 30():10732748221148912. PubMed ID: 36592162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
    Zhou T; Yang Y; Ma S; Lin L; Zhou T; Zhang C; Ding X; Wang R; Feng G; Chen Y; Xu R; Huang Y; Zhang L
    ESMO Open; 2021 Dec; 6(6):100313. PubMed ID: 34837744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
    Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
    Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
    Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.